Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.

Authors :: Tsoukas MA
Woo V
Tobe SW
Slee A
Rapattoni W
Ang FG
Seufert J
Neuen BL
Arnott C
Mahaffey KW
Wheeler DC
Source :: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Jul; Vol. 25 (7), pp. 2038-2042. Date of Electronic Publication: 2023 Apr 04.
Publication Year :: 2023

Subjects :: Humans
Canagliflozin therapeutic use
Kidney
Diabetes Mellitus, Type 2 complications
Diabetes Mellitus, Type 2 drug therapy
Cardiovascular System
Cardiovascular Diseases epidemiology
Cardiovascular Diseases prevention & control

Full Text Access

Tools